Home LiteratureArticle Details
PMID: 12102655 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein.

The Biochemical journal ·Vol. 367 ·No. Pt 2 ·2002-10-15 ·Pages 403-12

Taskinen S, Kovanen PT, Jarva H, Meri S, Pentikäinen MO

Abstract

C-reactive protein (CRP), an acute-phase reactant, is present in atherosclerotic human arterial intima in association with lipids. In the present work we studied interactions between CRP and LDL on microtitre wells, where either CRP or LDL was immobilized. LDL was modified by vortex-mixing, oxidation, or by lipolysis with phospholipase A(2) or with sphingomyelinase or a combination of trypsin and cholesterol esterase. We found that CRP bound only to LDL modified by trypsin/cholesterol esterase or by sphingomyelinase and that this binding was Ca(2+)-dependent. In these two forms of modified LDL, non-esterified cholesterol was susceptible to cholesterol oxidase, indicating exposure of non-esterified cholesterol on particle surfaces and suggesting a role for non-esterified cholesterol in mediating CRP binding. Consistent with this hypothesis were the following findings: (i) increasing the amount of non-esterified cholesterol in LDL with cyclodextrin increased, and decreasing its amount decreased, the binding of CRP to LDL; (ii) modification of non-esterified cholesterol in LDL by cholesterol oxidase decreased the binding of CRP to LDL; and (iii) CRP bound to purified non-esterified cholesterol. The binding was Ca(2+)-dependent and could be competed out with phosphocholine. Taken together, these findings suggest that CRP can bind to modified lipoproteins, notably to the non-esterified cholesterol on their surface. These interactions may be related to the suggested role of CRP in the local inflammation present in atherosclerotic plaques.

MeSH Terms
Arteriosclerosis/metabolism C-Reactive Protein Calcium/metabolism Cholesterol/metabolism Cyclodextrins/chemistry Humans Ligands Lipoproteins, LDL/chemistry,metabolism Oxidation-Reduction Phosphatidylcholines/chemistry,metabolism Phospholipases A/chemistry,metabolism Sphingomyelin Phosphodiesterase/chemistry,metabolism Sterol Esterase/chemistry,metabolism Trypsin/chemistry,metabolism
Chemicals
Cyclodextrins Ligands Lipoproteins, LDL Phosphatidylcholines C-Reactive Protein Cholesterol Sterol Esterase Phospholipases A Sphingomyelin Phosphodiesterase Trypsin Calcium
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Taskinen Sanna
Wihuri Research Institute, Kalliolinnantie 4, FIN-00140 Helsinki, Finland.
Kovanen Petri T
Jarva Hanna
Meri Seppo
Pentikäinen Markku O
References (51)
51 references, click to expand
  1. Modified LDL - trigger of atherosclerosis and inflammation in the arterial intima.
    J Intern Med. 2000 Mar;247(3):359-70 PMID: 10762453
  2. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity.
    J Exp Med. 2000 Nov 6;192(9):1353-64 PMID: 11067883
  3. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL.
    Biochim Biophys Acta. 2000 Nov 15;1488(3):189-210 PMID: 11082530
  4. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis.
    Circulation. 2001 Mar 6;103(9):1194-7 PMID: 11238260
  5. Lipolysis of LDL by human secretory phospholipase A(2) induces particle fusion and enhances the retention of LDL to human aortic proteoglycans.
    Arterioscler Thromb Vasc Biol. 2001 Jun;21(6):1053-8 PMID: 11397719
  6. Monoclonal antibody detection of plasma membrane cholesterol microdomains responsive to cholesterol trafficking.
    J Lipid Res. 2001 Sep;42(9):1492-500 PMID: 11518770
  7. Myeloperoxidase and hypochlorite, but not copper ions, oxidize heparin-bound LDL particles and release them from heparin.
    Arterioscler Thromb Vasc Biol. 2001 Dec;21(12):1902-8 PMID: 11742862
  8. Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide.
    Proc Soc Exp Biol Med. 1971 Feb;136(2):612-4 PMID: 4395924
  9. The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent.
    Biochem J. 1973 Jul;133(3):529-39 PMID: 4733239
  10. Interactions of C-reactive protein with the first component of human complement.
    J Immunol. 1977 Jul;119(1):187-92 PMID: 17637
  11. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers.
    Nature. 1979 Sep 13;281(5727):155-7 PMID: 471064
  12. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction.
    J Exp Med. 1999 Dec 20;190(12):1733-40 PMID: 10601349
  13. Cholesterol oxidation switches the internalization pathway of endothelin receptor type A from caveolae to clathrin-coated pits in Chinese hamster ovary cells.
    J Biol Chem. 2000 Mar 3;275(9):6439-46 PMID: 10692447
  14. Binding reactivity of C-reactive protein for polycations.
    J Immunol. 1980 Nov;125(5):1933-8 PMID: 6776184
  15. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein.
    J Exp Med. 1982 Jul 1;156(1):230-42 PMID: 7086355
  16. Binding of fibronectin by the acute phase reactant C-reactive protein.
    J Biol Chem. 1984 Feb 10;259(3):1496-501 PMID: 6693419
  17. Rabbit and rat C-reactive proteins bind apolipoprotein B-containing lipoproteins.
    J Exp Med. 1984 Feb 1;159(2):604-16 PMID: 6693835
  18. Binding of C-reactive protein to chromatin and nucleosome core particles. A possible physiological role of C-reactive protein.
    J Biol Chem. 1984 Jun 10;259(11):7311-6 PMID: 6427230
  19. Quantitative determinations of immunoglobulins and complement components in human aortic atherosclerotic wall.
    Med Interne. 1985 Jan-Mar;23(1):29-35 PMID: 3992145
  20. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas.
    Arch Pathol Lab Med. 1987 Mar;111(3):265-9 PMID: 2435257
  21. Expression of a C-reactive protein neoantigen (neo-CRP) in inflamed rabbit liver and muscle.
    Clin Immunol Immunopathol. 1988 Jul;48(1):95-107 PMID: 2454772
  22. C-reactive protein reacts with the U1 small nuclear ribonucleoprotein.
    J Immunol. 1989 Oct 15;143(8):2553-9 PMID: 2477447
  23. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells.
    Proc Natl Acad Sci U S A. 1990 Jul;87(13):5134-8 PMID: 1695010
  24. Oxidation of cholesterol in low density and high density lipoproteins by cholesterol oxidase.
    J Lipid Res. 1990 Dec;31(12):2235-42 PMID: 2090717
  25. Hydrolysis of cholesteryl ester in low density lipoprotein converts this lipoprotein to a liposome.
    J Biol Chem. 1992 Mar 5;267(7):4992-8 PMID: 1537875
  26. Hydroxypropylcyclodextrins in parenteral use. I: Lipid dissolution and effects on lipid transfers in vitro.
    J Pharm Sci. 1992 Jun;81(6):521-3 PMID: 1522487
  27. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl.
    J Exp Med. 1995 Nov 1;182(5):1545-56 PMID: 7595224
  28. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety.
    J Exp Med. 1995 Dec 1;182(6):1959-71 PMID: 7500042
  29. Three dimensional structure of human C-reactive protein.
    Nat Struct Biol. 1996 Apr;3(4):346-54 PMID: 8599761
  30. Cellular cholesterol efflux mediated by cyclodextrins. Demonstration Of kinetic pools and mechanism of efflux.
    J Biol Chem. 1996 Jul 5;271(27):16026-34 PMID: 8663188
  31. Secretory group II phospholipase A2 in human atherosclerotic plaques.
    Atherosclerosis. 1995 Dec;118(2):173-81 PMID: 8770312
  32. Aggregation and fusion of modified low density lipoprotein.
    J Lipid Res. 1996 Dec;37(12):2638-49 PMID: 9017515
  33. Potential involvement of type II phospholipase A2 in atherosclerosis.
    Atherosclerosis. 1997 Jul 11;132(1):1-8 PMID: 9247353
  34. Oxidation of low density lipoprotein particles decreases their ability to bind to human aortic proteoglycans. Dependence on oxidative modification of the lysine residues.
    J Biol Chem. 1997 Aug 22;272(34):21303-11 PMID: 9261142
  35. The perturbed membrane of cells undergoing apoptosis is susceptible to type II secretory phospholipase A2 to liberate arachidonic acid.
    Biochim Biophys Acta. 1997 Nov 8;1349(1):43-54 PMID: 9421195
  36. Physical effects of cholesterol on arterial smooth muscle membranes: evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis.
    J Lipid Res. 1998 May;39(5):947-56 PMID: 9610760
  37. Atherogenic properties of enzymatically degraded LDL: selective induction of MCP-1 and cytotoxic effects on human macrophages.
    Arterioscler Thromb Vasc Biol. 1998 Sep;18(9):1376-85 PMID: 9743225
  38. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries.
    Arterioscler Thromb Vasc Biol. 1998 Sep;18(9):1386-92 PMID: 9743226
  39. Biodistribution and clearance of 125I-labeled C-reactive protein and 125I-labeled modified C-reactive protein in CD-1 mice.
    Drug Metab Dispos. 1998 Oct;26(10):977-81 PMID: 9763402
  40. Atherosclerosis--an inflammatory disease.
    N Engl J Med. 1999 Jan 14;340(2):115-26 PMID: 9887164
  41. Calcium-dependent binding of rabbit C-reactive protein to supported lipid monolayers containing exposed phosphorylcholine group.
    Biophys J. 1999 Jan;76(1 Pt 1):333-41 PMID: 9876145
  42. Conversion of native oligomeric to a modified monomeric form of human C-reactive protein.
    Int J Biochem Cell Biol. 1998 Dec;30(12):1415-26 PMID: 9924810
  43. Enzymatically modified, nonoxidized LDL induces selective adhesion and transmigration of monocytes and T-lymphocytes through human endothelial cell monolayers.
    Arterioscler Thromb Vasc Biol. 1999 Mar;19(3):784-93 PMID: 10073987
  44. Phosphorylcholine: friend or foe of the immune system?
    Immunol Today. 1999 Mar;20(3):125-9 PMID: 10203703
  45. The major receptor for C-reactive protein on leukocytes is fcgamma receptor II.
    J Exp Med. 1999 Aug 16;190(4):585-90 PMID: 10449529
  46. Coronary C-reactive protein distribution: its relation to development of atherosclerosis.
    Atherosclerosis. 1999 Aug;145(2):375-9 PMID: 10488966
  47. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11.
    J Immunol. 1999 Oct 1;163(7):3957-62 PMID: 10490997
  48. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation.
    Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2348-54 PMID: 10521363
  49. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.
    J Clin Invest. 1955 Sep;34(9):1345-53 PMID: 13252080
  50. A rapid method of total lipid extraction and purification.
    Can J Biochem Physiol. 1959 Aug;37(8):911-7 PMID: 13671378
  51. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin.
    J Immunol. 1974 Jun;112(6):2135-47 PMID: 4151108
Article Info
Journal
The Biochemical journal
Abbr.
Biochem J
ISSN
0264-6021
Published
2002-10-15
Pages
403-12
Language
English
Region
England
NLM ID
2984726R
PMCID
PMC1222894
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com